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The remarkable clinical efficacy of anti-CD20 monoclonal antibodies (mAb) in relapsing-
remitting multiple sclerosis points at the critical involvement of B cells in the disease.
However, the exact pathogenic contribution of B cells is poorly understood. In this publica-
tion we review new data on the role of CD20+B cells in a unique experimental autoimmune
encephalomyelitis (EAE) model in common marmosets (Callithrix jacchus), a small-bodied
neotropical primate.We will also discuss the relevance of these data for MS. Different from
rodent EAE models, but similar to MS, disease progression in marmosets can develop
independent of autoantibodies. Progressive disease is mediated by MHC class Ib (Caja-
E) restricted cytotoxic T cells, which are activated by γ-herpesvirus-infected B cells and
cause widespread demyelination of cortical gray matter. B-cell directed monoclonal anti-
body therapies (anti-CD20 versus anti-BLyS and anti-APRIL) have a variable effect on EAE
progression, which we found associated with variable depletion of the Epstein Barr virus
(EBV)-like γ-herpesvirus CalHV3 from lymphoid organs.These findings support an important
pathogenic role of CD20 B cell in MS, especially of the subset infected with EBV.+
Keywords: MS, EAE, EBV, non-human primate, B cell,T cell, immunotherapy
INTRODUCTION
Multiple sclerosis (MS) is generally viewed as a neuroinflamma-
tory disease initiated by a CD4+ T cell led autoimmune attack
on the central nervous system (CNS), culminating into inflam-
mation and tissue injury (Sospedra and Martin, 2005). Although
the cause of MS is not known, infection of genetically susceptible
individuals with (as yet unidentified) pathogen(s) is considered a
likely trigger of CNS targeting cellular and humoral autoimmune
reactions. Once induced, autoimmunity against myelin and non-
myelin antigens drives progression of the disease to irreversible
neurological deficit.
The prevailing concepts of MS pathogenesis are strongly influ-
enced by the experimental autoimmune encephalomyelitis (EAE)
animal model. However, although the relevance of the EAE model
for our understanding of the autoimmune processes in MS has
been enormous, the translation of EAE-based pathogenic concepts
to the MS patient has often failed. The conceptual gap between the
EAE model and MS is probably best illustrated by new treatments
that fail to reproduce promising beneficial effects observed in the
EAE model when they were tested in MS patients.
A well-recognized complication in preclinical therapy develop-
ment is the immunological gap between inbred/SPF raised mouse
strains used for MS modeling and the genetically and microbi-
ologically heterogeneous patient population (Sachs, 2003; Davis,
2008). This probably also explains why certain pathogenic aspects
of MS are not recapitulated in classical mouse EAE models –
including the conversion from relapsing-remitting to progressive
disease, a presumed prominent pathogenic role of CD8+ T cells
and demyelination in cortical gray matter. The question is war-
ranted whether these characteristic features of MS progression
may be more accurately replicated in species that are more closely
related to humans.
In this review we will present new data from immunopathogen-
esis and immunotherapy studies in a well-validated non-human
primate EAE model that can help bridge the gap as it shares impor-
tant similarities with rodent EAE as well as with MS. After briefly
reviewing the role of T cells in the models, we will focus the discus-
sion on a mechanistic explanation for the remarkable efficacy of
B-cell depletion with anti-CD20 monoclonal antibodies (mAbs)
(reviewed in Barun and Bar-Or, 2012) and for the still elusive asso-
ciation of Epstein Barr Virus (EBV) infection with MS (reviewed
in Ascherio and Munger, 2007; Lunemann et al., 2007).
ANIMAL MODELS OF MS
Multiple sclerosis researchers have only limited possibilities for
investigating in patients immunological mechanisms that drive
the disease and the ensuing pathological events within brain
and spinal cord. Animal models have therefore been very impor-
tant for the development of pathogenic and therapeutic concepts
(reviewed in Ransohoff, 2012). The mouse is the most frequently
chosen model for translational research into MS. A plethora of
experimental models is now available, although only a limited
number of susceptible strains (C57BL/6, SJL, BALB/c, Biozzi ABH)
is used.
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As reviewed in more detail elsewhere, clinical and pathological
aspects of MS can be elicited via virus infection, by active immu-
nization or by passive transfer of autoreactive T cells (reviewed
in ‘T Hart et al., 2011). More sophisticated are the models in
transgenic mice where MS-like pathology and disease develop
spontaneously (Krishnamoorthy et al., 2007; ‘T Hart et al., 2011).
Although mouse models have been extremely valuable for our
understanding of neuroimmune deviations in MS, the translation
of new pathogenic concepts into effective treatments for MS has
been notoriously difficult thus far (Steinman and Zamvil, 2006; ‘T
Hart et al., 2011). This has triggered criticism on the relevance of
EAE model as a preclinical model of MS (Sriram and Steiner, 2005;
Ransohoff, 2006, 2012). Nevertheless, several effective treatments,
natalizumab for example, are directly based on preclinical research
in this model (Steinman, 2005).
Throughout the years, the EAE model in common marmosets,
a small-bodied neotropical primate, has been important for the
efficacy testing of biological treatments, which due to their species-
specificity cannot be tested in the more widely used rodent EAE
models (‘T Hart and Bajramovic, 2008; ‘T Hart et al., 2011).
THE ELUSIVE ROLE OF B CELLS
The clinical efficacy of systemic B-cell depletion by anti-CD20
mAbs in relapsing-remitting multiple sclerosis (RRMS) was rather
unexpected, as literature data on the exact role of B cells in EAE and
MS are confusing and sometimes paradoxical. The traditional role
of B cells in widely adhered EAE-based autoimmune concepts of
MS is considered less prominent than the role of pro-inflammatory
Th1/Th17 cells, namely the production of autoantibodies that
mediate injury to axon enwrapping myelin sheaths (demyelina-
tion) via complement- and macrophage-dependent cytotoxicity
reactions (Krumbholz et al., 2012). However, experiments in trans-
genic mice show that autoreactive T and B cells are both needed for
the induction of full-blown demyelinating disease (Pollinger et al.,
2009). On the other hand, EAE studies in mice (Oliver et al., 2003)
as well as non-human primates (NHP) (Jagessar et al., 2010) show-
ing that autoimmune demyelination of CNS white matter can be
induced independent of autoantibodies, warrant questions on the
exact pathogenic role of B cells.
Therapeutic mAbs that target both the T- and B-cell arms of the
autoimmune attack show promising effects in RRMS. Examples
are alemtuzumab, a depleting mAb against CD52 expressed on B
cells, T cells and monocytes (Klotz et al., 2012), and natalizumab, a
blocking mAb against α4β1 integrin that blocks the CNS immigra-
tion of these cell types (Engelhardt and Kappos, 2008). However,
mAbs that preferentially target pro-inflammatory CD4+ T helper
(Th)1 cells such as anti-CD4 mAb (Racadot et al., 1993; Lind-
sey et al., 1994; van Oosten et al., 1996) or that interfere with
the differentiation of antigen-activated CD4+ T cells toward Th1,
such as the anti-IL-12p40 mAb ustekinumab, have shown only
moderate or no effects (Segal et al., 2008). By contrast, selective
depletion of B cells via mAbs against the B lineage specific surface
marker CD20 (rituximab, ocrelizumab, and ofatumumab) proved
remarkably effective in the induction of long-lasting suppression
of lesion activity and clinical relapses (Barun and Bar-Or, 2012).
On the other hand, induction of peripheral B-cell depletion via
a soluble receptor of the TACI receptor (atacicept) for the B-cell
cytokines BlyS (B lymphocyte stimulator; also known as BAFF)
and APRIL (A Proliferation Inducing Ligand) did not suppress
disease activity in RRMS (Hartung and Kieseier, 2010). Rather
unexpectedly suppression of lesion activity and/or clinical symp-
toms by anti-CD20 mAb was not consistently associated with a
reduction of serum autoantibody levels (Krumbholz et al., 2012).
In conclusion, although results from therapy trials in RRMS
seem to confirm the important pathogenic role of T as well as B
cells, they conflict with the classical concept that MS is caused by a
combined autoimmune attack by Th1 cells causing inflammation
and autoantibody producing B cells causing demyelination. How
can this paradox be explained?
We will review here new data on the pathogenic role of CD20+
B cells in the unique EAE model in common marmosets. The
model closely resembles MS in its immunological complexity
and its clinical and pathological presentation (‘T Hart and Mas-
sacesi, 2009) and is therefore particularly suitable for translational
research into pathogenic mechanisms and the influence of genetic
and environmental factors. After a concise summary of the cellular
autoimmune events that drive disease initiation and progression
in the model, we will zoom in on the role of B cells. The dissection
of the model into its main pathogenic components in combina-
tion with efficacy analysis of B-cell targeting therapeutic mAbs,
has led us to postulate that the activation of CNS myelin specific
cytotoxic T cells, which have a core pathogenic role in the chronic
phase of the model (‘T Hart et al., 2011), is mediated by γ-herpes
virus-infected B cells.
CONCISE OVERVIEW OF THE MARMOSET EAE MODEL
The central difference between EAE models in immunologically
naïve inbred/SPF rodents and in the adult outbred conventionally
housed NHP is that the disease in NHP develops in an immune
environment that is shaped by genetic diversity and the daily com-
bat with new and opportunistic infections. The consequences of
the more human-like genetic, immunological, and microbiologi-
cal condition of NHP for the clinical and pathological presentation
of EAE have been extensively studied in the common marmoset
(‘T Hart and Massacesi, 2009).
In brief, we found that among the complex patterns of autoim-
mune reactions developing in marmosets sensitized against CNS
myelin, T- and B-cell responses against the quantitatively minor
myelin oligodendrocyte glycoprotein (MOG) are critical for the
development of chronic EAE (Jagessar et al., 2008).
The subsequently developed EAE model in marmosets, induced
with recombinant human MOG1–125 (rhMOG) formulated with
complete Freund’s adjuvant (CFA), can be characterized as “half
mouse, half man.” The two-faced character of the model is
reflected by the existence of two non-overlapping pathogenic
mechanisms, a mouse EAE-like initiation pathway and a human
MS-like progression pathway (see summary in Table 1) (‘T Hart
et al., 2011).
THE EAE INITIATION PATHWAY
Just like in classical mouse EAE models, immunization of mar-
mosets with rhMOG formulated with CFA induces the activation
of Th1 cells and autoantibodies. The Th1 cells are specific for the
epitope MOG24–36 and activation is restricted by a monomorphic
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Table 1 | Characteristics of the two autoimmune pathways proposed
to elicit clinically evident EAE in marmosets immunized with
rhMOG/CFA.
Pathway 1 Pathway 2
Main activity EAE induction EAE progression
Immune signature
T cell mediator Anti-MOG24–36 Th1 Anti-MOG40–48 NK-CTL
role Th17 cells uncertain
MHC restriction Caja-DRB *W1201 Caja-E
Suppressed by Anti-IL-12p40 mAb Anti-CD20 mAb
Anti-CD20 mAb
Anti-CD40 mAb






A detailed discussion of the two pathways is provided in ‘T Hart et al. (2011).
Anti-CD40 is an antagonist antibody blocking APC-T cell interaction.
MHC class II allele (Caja-DRB1∗W1201). Th1 cells induce inflam-
mation in the white matter of brain and spinal cord (Brok et al.,
2000; Doxiadis et al., 2006; Kap et al., 2008). Demyelination is
also induced, but is mediated by autoantibodies that bind con-
formationally intact MOG and elicit cytotoxicity by macrophages
(ADCC) or complement (CDC). The separation of effector mech-
anisms is illustrated by the finding that demyelination in mar-
mosets immunized with MP4, a chimeric protein composed of
myelin basic protein (MBP) and proteolipid protein (PLP), devel-
oped only in monkeys that formed anti-MOG antibodies (McFar-
land et al., 1999). Moreover, it was shown that adoptive transfer
of an anti-MOG21–40 Th1 cell clone (Villoslada et al., 2001)
induced only white matter inflammation and that demyelination
in monkeys immunized with MBP or PLP could be induced by
adoptive transfer of a monoclonal antibody (mAb) against rat
MOG (8.18.C5) (Genain et al., 1995).
The finding that early treatment with the anti-IL-12p40 mAb
ustekinumab completely abrogates EAE development illustrates
the pathogenic relevance of the mouse EAE-like initiation path-
way (‘T Hart et al., 2005). However, when the treatment with
ustekinumab was installed at a later phase of the disease, when
brain white matter lesions had already been formed, the efficacy
was much lower, although the activity of the lesions (inflammation
and enlargement) was completely suppressed (‘T Hart et al., 2005).
We therefore hypothesized that during the course of the disease, a
second pathogenic mechanism might be activated. A possible trig-
ger may be the release of self antigens from lesions inflicted by the
concerted action of Th1 cells and autoantibodies that we discussed
above (‘T Hart et al., 2009). The existence of a second EAE perpet-
uation mechanism could indeed be confirmed (Kap et al., 2008).
THE EAE PROGRESSION PATHWAY
In monkeys with a relatively rapid EAE progression T cell reac-
tivity against peptide MOG34–56 was detected (Kap et al., 2008).
By serial magnetic resonance imaging (MRI) it was observed that
the appearance of this reactivity occurs side-by side with a typical
late-stage event in the rhMOG/CFA model, namely the induction
of demyelination in the cortical gray matter (‘T Hart et al., 2004).
We identified the phenotype, fine-specificity and MHC restriction
of the MOG34–56 responsive T cell fraction via carboxyfluorescein
succinimidyl ester (CFSE) vital dye dilution. The main propor-
tion of the anti-peptide reactivity was found in a subpopulation
of CD3+CD4+CD8α+CD56+CD28−CD27+CD16−CCR7− T
cells (Kap et al., 2008; Jagessar et al., 2012b). The main functional
characteristics of the cells were high production of IL-17A and
specific cytotoxicity toward EBV-transformed B cells presenting
peptides derived from MOG34–56. Based on the similarity of this
phenotype and function with a subset of NK cell related cytotoxic
T cells in the human immune system (Mazzarino et al., 2005)
we proposed to name this subset natural-killer-cytotoxic T lym-
phocytes (NK-CTL). The specificity of these core pathogenic T
cells was defined at MOG40–48 and the presenting MHC mole-
cule as Caja-E (Jagessar et al., 2012b). In the IPD-MHC database
(http://www.ebi.ac.uk/ipd/mhc/nhp/index.html) only two Caja-E
alleles are published, indicating that, just like the human ortholog
HLA-E, Caja-E is oligomorphic. The only difference between the
two alleles is a single amino acid at position 123 (V or L) located
outside the peptide-binding cleft. The expression of Caja-E within
the marmoset brain was confirmed (Jagessar et al., 2012b).
We observed that the NK-CTL is directly activated in mon-
keys immunized with peptide MOG34–56 in incomplete Freund’s
adjuvant (MOG34–56/IFA) (Jagessar et al., 2010). This exciting new
model shows remarkable pathological similarity with progressive
MS, in particular the presence of widespread demyelination in the
cortical gray matter. Intriguingly, IgM and IgG antibodies bind-
ing ELISA plate-bound rhMOG, which is a requirement for their
capacity to mediate demyelination (Menge et al., 2007), are not
detectable in this model. Neither were such antibodies found in
the circulation, nor was deposition of antibody and complement
within the CNS detectable. For this reason we held the autore-
active cytotoxic T cells responsible for the cortical demyelination
(Jagessar et al., 2012b).
Are these findings relevant for MS? It has been documented
that the immune repertoire of MS patients is significantly enriched
with high avidity CD4+T cells against MOG34–56 (Bielekova et al.,
2004). Others showed that the MS repertoire contains HLA-E
restricted cytotoxic T cells that are capable to kill oligodendro-
cytes. These cytotoxic T cells display remarkable similarities with
the Caja-E restricted cytotoxic T cells that drive MOG34–56/IFA
induced EAE in marmosets (Broux et al., 2012; Zaguia et al., 2013).
The specific epitopes of the Th1 cells that drive the initiation path-
way (MOG34–36) and of the CTL that drive the progression path-
way (MOG40–48) are juxta-positioned in an evolutionary highly
conserved area (20–50) of the MOG extracellular domain. The
only difference between evolutionary distinct species is at posi-
tion 42, which is occupied by serine (S42 in MOG from mouse,
rat, marmoset) or proline (P42 in MOG from man, rhesus, or
cynomolgus macaque) (Table 2).
In summary, the rhMOG/CFA marmoset EAE model illustrates
the difficulties encountered in the translation of therapeutic prin-
ciples from the EAE model to the MS patient. The EAE initiation
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Table 2 | Alignment of amino acids sequences of the myelin oligodendrocyte glycoprotein extracellular domain (MOG1–125).
1 10 20 30 # 40 50 60
human GQFRVIGPRH PIRALVGDEV ELPCRISPGK NATGMEVGWY RPPFSRVVHL YRNGKDQDGD
M. mulatta* GQFRVIGPRQ PIRALVGDEV ELPCRISPGK NATGMEVGWY RPPFSRVVHL YRNGRDQDGE
M. fascicularis* GQFRVIGPRQ PIRALVGDEV ELPCRISPGK NATGMEVGWY RPPFSRVVHL YRNGRDQDGE
marmoset GQFRVIGSRH PIQALVGDAA ELPCRISPGK NATGMEVGWY RSPFSRVVHL YRNGKDQDGE
mouse GQFRVIGPGY PIRALVGDEA ELPCRISPGK NATGMEVGWY RSPFSRVVHL YRNGKDQDAE
rat GQFRVIGPGH PIRALVGDEA ELPCRISPGK NATGMEVGWY RSPFSRVVHL YRNGKDQDAE
70 80 90 100 110 120 125
human QAPEYRGRTE LLKDAIGEGK VTLRIRNVRF SDEGGFTCFF RDHSYQEEAA MELKVEDPFY WVSPG
M. mulatta* QAPEYRGRTE LLKDAIGEGK VTLRIRNVRF SNEGGFTCFF RDHSYQEEAA IELKVEDPFY WVSPA
M. fascicularis* QAPEYRGRTE LLKDAIGEGK VTLRIRNVRF SDEGGFTCFF RDHSYQEEAA IELKVEDPFY WVSPA
marmoset QAPEYRGRTE LLKDDIGEGK VTLKIRNVRF PDEGGFTCFF RDHSYQEEAA MQLKVEDPFY WVSPG
mouse QAPEYRGRTE LLKETISEGK VTLRIQNVRF SDEGGYTCFF RDHSYQEEAA MELKVEDPFY WVNPG
rat QAPEYRGRTE LLKESIGEGK VALRIQNVRF SDEGGYTCFF RDHSYQEEAA VELKVEDPFY WINPG
MOG sequences were down-loaded from http:// www.uniprot.org/ uniprot/ ?query=myelin+oligodendrocyte+glycoprotein&offset=25&sort=score. All positions
where there is variation between the species are marked bold and in red. The two identified dominant T cell epitopes identified in marmosets (for the CD4 Th1:
MOG24–36 and for the CD4+CD8+CD56+ NK-CTL: MOG40–48) are juxtaposed in the highly conserved domain MOG21–50. The only N-glycosylation site in MOG
is also located in this domain, namely Asn31 (#).
pathway in marmosets recapitulates classical mouse EAE models.
Despite the highly relevant pathogenic role of the IL-12/IL-23 axis
in mouse EAE models (Gran et al., 2004), which was reproduced
by the promising efficacy of the anti-IL-12p40 mAb ustekinumab
in the marmoset EAE model, the ustekinumab mAb lacked effi-
cacy when tested in RRMS (‘T Hart et al., 2005; Segal et al., 2008).
A possible explanation for this discrepancy may be that the mouse
EAE-like initiation pathway has long passed when the diagnosis
MS is first made. The question is therefore warranted whether
the MOG34–56/IFA induced marmoset EAE model more closely
resembles established MS.
A CRUCIAL ROLE OF CD20+ B CELLS IN THE MARMOSET EAE
MODEL
Several B-cell targeting therapies are now under development for
therapeutic application in human autoimmune diseases (review:
Davidson, 2010; Barun and Bar-Or, 2012). The specificities include
CD20, a broadly expressed surface marker in the B-cell lineage, and
the cytokines BlyS and APRIL, which exert overlapping activities
on the survival and development of B cells (Figure 1).
Clinical trials with a chimeric anti-CD20 mAb (rituximab)
show remarkable beneficial effects on clinical and MRI para-
meters in RRMS, subgroups of primary progressive MS, and in
opticospinal disease (Barun and Bar-Or, 2012). Administration
of anti-CD20 mAb induced rapid, profound, and long-lasting
(months) depletion of B cells from blood and, albeit less profound,
from the cerebrospinal fluid (Cross et al., 2006). However, the
mechanisms underlying the remarkable and unexpected beneficial
effects of B-cell depletion in MS are incompletely understood.
Studies in mouse EAE models show that B cells have a variety
of effects, which depend on the stage of the disease. The produc-
tion of anti-myelin autoantibodies that mediate demyelination via
the activation of ADCC and CDC has already been mentioned. A
most compelling set of data was reported by Matsushita et al.
(2008) who observed in B6 mice that early depletion of B cells
inhibited EAE due to abrogation of autoantibodies, whereas late
B-cell depletion can augment EAE severity due to the depletion of
IL-10+ regulatory B cells. Another study showed that the effect of
B-cell depletion varies between EAE models (Weber et al., 2010).
In B6 mice immunized with recombinant mouse MOG protein in
CFA, B-cell depletion suppressed EAE, by inhibiting the induction
of cellular (Th1, Th17) and humoral (autoantibody) autoimmune
reactions. In this model, B cells are activated and they process
and present MOG to the pro-inflammatory T cells. By contrast,
in B6 mice immunized with MOG35–55/CFA depletion of B cells
aggravated EAE, possibly because regulatory T cell activity was
impaired.
For the preclinical efficacy studies in the marmoset EAE model
we used HuMab7D8,a clonal variant of the fully human anti-CD20
IgG1κ mAb ofatumumab (Bleeker et al., 2008). Ofatumumab is
effective in MS (Barun and Bar-Or, 2012) and HuMab7D8 cross-
reacts well with marmoset B cells (Kap et al., 2010). The mAb
was successfully tested in the rhMOG/CFA model, where anti-
MOG autoantibodies have a pathogenic contribution, and in the
MOG34–56/IFA model, where anti-rhMOG autoantibodies are
not found (see below). All studies were designed to avoid inter-
ference with the immunization. Hence, the mAb treatment was
started well after the EAE induction, i.e., at post-sensitization (psd)
day 21. At this stage the autoimmune process is already ongoing, as
illustrated by the presence of anti-rhMOG IgG in the serum (Kap
et al., 2010).
HuMab7D8 IN THE rhMOG/CFA MODEL
The anti-CD20 mAb induced profound depletion of CD20+ B
cells from peripheral blood, lymphoid organs,and prevented B-cell
entry into the brain (Kap et al., 2010, 2011). The usually observed
progressive increase of serum anti-rhMOG IgG levels measured
in the control group was almost immediately stopped in treated
monkeys illustrating the brisk systemic effect of the mAb. The clin-
ical effect was remarkable as none of the mAb-treated monkeys
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FIGURE 1 | Differential mechanisms and distinct EAE outcome of B-cell
directed therapies. (A) B-cell targeting therapies tested in the marmoset
EAE model are neutralizing monoclonal antibodies (mAbs) against BLyS and
APRIL and a depleting mAb against CD20 (indicated with the symbol Y). BLyS
and APRIL are related cytokines expressed by myeloid and lymphoid cells
with a specific action on B cells. B cells express three types of receptors;
BAFF-R is specific for BLyS, whereas BCMA and TACI bind both factors. (B)
Since the target of anti-CD20 mAbs is expressed throughout B-cell
development, with the exception of pro-B-cells and plasma cells at the
extreme ends, anti-CD20 mAb depletes a wide range of B cells. The narrower
activity window of neutralizing antibodies against BLyS or APRIL or a soluble
form of TACI (atacicept) shows partial overlap with the expression of CD20.
developed evident clinical EAE; the formation of demyelinated
lesions in the gray and white matter of brain and spinal cord was
also dramatically reduced. Intriguingly, also the production of T
cell and macrophage cytokines that have a key function in the
EAE pathogenesis, such as IFNγ, IL-17A, TNF-α, and IL-7, was
impaired.
HuMab7D8 IN THE MOG34–56/IFA MODEL
As discussed above, the pathogen-educated immune system of
marmosets contains effector memory T cells, which express CD4,
CD8α, CD27, and CD56, but are negative for CD28 and CCR7
(Jagessar et al., 2012a). These T cells are the central drivers of
inflammation and demyelination in the EAE model induced with
MOG34–56/IFA (Jagessar et al., 2010). The model recapitulates clin-
ical and pathological features of the more complex rhMOG/CFA
EAE model, although it was induced without ligands for innate
antigen receptors in the immunizing inoculum and anti-rhMOG
autoantibodies could not be detected in the sera from immunized
monkeys (Jagessar et al., 2010). Although the exact pathogenic
mechanisms via which the autoreactive T cells elicit EAE pathol-
ogy and symptoms in this model have only partially been resolved,
a pathogenic role of the high production of IL-17A, and the Caja-E
restricted cytotoxicity toward EBV-transformed B cells presenting
the MOG40–48 core epitope is likely (Jagessar et al., 2012b). Strik-
ingly, weekly administration of HuMab7D8 from psd 21 onward
completely abrogated EAE development in this model. The activ-
ity of the antibody was reflected by a variable effect on the T cell
compartment, measured at necropsy (Jagessar et al., 2012a). The
ex vivo proliferation of blood mononuclear cells (PBMC) induced
with MOG34–56 was not significantly different between the control
and anti-CD20 treated monkeys. Whereas mRNA transcript levels
of perforin and granzyme B, both markers of the NK-CTL, were
reduced in axillary lymph nodes (ALN), we observed no changes
in spleen. By contrast, mRNA levels of IFNγ and IL-17A were
reduced in spleen but increased in the ALN. These data suggest
that the effect of B-cell depletion may not be prevention of T cell
activation. One possible explanation may be that the distribution
of the pathogenic T cells over the secondary lymphoid organs and
the target organ may be altered by the depletion of B cells. We are
therefore performing a systemic analysis of T cell activity profiles
in the whole lymphoid compartment. However, these data are not
yet available.
The results of both studies warrant the conclusion that
B cells have a key pathogenic role in the marmoset EAE
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model. The pathogenic function of the B cells includes, but
is likely not confined to, the activation of Caja-E restricted
CD3+CD4+CD8α+CD56+ effector memory cytotoxic T cells
that induce MS-like pathology in cortical gray matter.
MODERATE EFFICACY OF ANTI-BLyS AND ANTI-APRIL mABS
IN rhMOG/CFA EAE
The obvious key question in this context is whether all CD20+
B cells are capable to activate the core pathogenic subset of cyto-
toxic T cells or whether this capacity is confined to a certain B cell
subpopulation. To address this issue, we tested the efficacy of two
neutralizing mAbs against the growth and survival factors BLyS
and APRIL, which B cells need for their survival and development
(see Figure 1).
The B-cell cytokines BLyS and APRIL are members of the TNF
superfamily, expressed by a wide range of myeloid and lymphoid
cells, B cells included (Rickert et al., 2011). The two cytokines
relay their stimulatory signals to B cells via three different recep-
tors: TACI and BCMA bind BlyS and APRIL, while BR3 binds only
BLyS (Figure 1A). The co-stimulatory signals relayed to B-cell
subsets enhance their survival and development. Deregulation of
BLyS has been associated with autoimmune disease in experimen-
tal models and human patients, such as with SLE, RA, or Sjögren
syndrome (Rickert et al., 2011). The BLyS inhibiting mAb beli-
mumab has recently received FDA approval for treatment of SLE
(Liu and Davidson, 2011). Atacicept, a recombinant fusion pro-
tein composed of human Ig-Fc fragment with the ligand binding
unit of TACI, the shared joined receptor of BLyS and APRIL, has
been evaluated in MS. However, two trials with atacicept had to be
stopped due to an unexpected increase of inflammatory activity
on brain MRI scans in one of the trials (Hartung and Kieseier,
2010).
The efficacy testing of anti-BLyS and anti-APRIL mAbs in the
rhMOG/CFA EAE model showed profound depletion of periph-
eral B cells, with the exception of a subset of CD40high B cells.
Intriguingly, this subpopulation was depleted in the monkeys
treated with anti-CD20 mAb (Jagessar et al., 2012a). However,
while the anti-CD20 mAb treatment completely prevented EAE
development, all monkeys treated with anti-BLyS and anti-APRIL
mAb developed clinically evident EAE albeit with a delayed onset
of about 2 weeks (Jagessar et al., 2012b).
How can the discrepant effects of anti-CD20 and anti-BlyS or
APRIL mAb be explained? The shortage of cross-reactive anti-
bodies with which B-cell subsets can be phenotyped has thus far
prohibited an in depth analysis of changes in the B-cell com-
partment induced by the different treatments. In the context of
the above-mentioned systems analysis we are developing such
markers.
One of the major differences between conventionally housed
NHP and SPF rodents is that NHP are infected with similar her-
pes viruses as those infecting humans. The marmoset equivalent of
human EBV, CalHV3, is a B-cell transforming lymphocryptovirus
(Cho et al., 2001). It is of note that EBV-infected B lymphoblastoid
cell lines of marmosets are CD20+, express high CD40 and pro-
duce BLyS, but are insensitive to BLyS inhibition by the anti-BLyS
mAb (Jagessar et al., 2013). This observation raised the ques-
tion whether the distinct effects of anti-CD20 and anti-BLyS mAb
could be explained by differential depletion of CalHV3-infected
B cells. We used a qPCR developed in-house for quantification
of CalHV3 DNA copy numbers developed in lymphoid organs.
Spleen and lymph nodes from non-treated EAE marmosets and
anti-BLyS treated EAE marmosets contained high CalHV3 titers,
whereas these were reduced>90% in EAE marmosets treated with
anti-CD20 mAb (Jagessar et al., 2013). This observation indeed
suggests that CalHV3 containing B cells are depleted in marmosets
treated with anti-CD20 mAb, but not or to a lesser extent in mar-
mosets treated with anti-BLyS mAb. It is tempting to speculate
that the discrepant efficacy of anti-CD20 mAbs and atacicept in
MS may be based on a similar mechanism.
TRANSLATION TO MS
We postulate that the efficacy of treatment with B-cell targeting
mAbs in the marmoset EAE model is related to the depletion of
CalHV3-infected B cells. The direct implication of this postulate
is that B cells infected with the virus have a crucial pathogenic role
in the EAE model.
An important question is the relevance for the treatment of
MS. There is a vast body of literature data supporting the associ-
ation of EBV infection with MS susceptibility (Christensen, 2007;
Lunemann and Munz, 2009; Pender, 2011), but the underlying
mechanism(s) remain poorly understood. Intriguingly, MS-like
diseases associated with γ-herpesvirus infection were recently
reported in mice (Casiraghi et al., 2012) and in macaques (Axthelm
et al., 2011). The marmoset EAE model suggests that infection with
the EBV-counterpart CalHV3 renders B cells capable of recruiting
autoreactive cytotoxic T memory cells from the normal repertoire.
Data obtained both in rhesus monkey and marmoset EAE models
indicate that the original trigger of these memory cells may be
another herpes virus, cytomegalovirus (CMV). Cytotoxic T cells
isolated from rhesus monkeys sensitized against MOG34–56 were
found to proliferate ex vivo against peptide 981–1003 from the
UL86 ORF-encoded major capsid protein, an immunodominant
antigen of CMV (Sylwester et al., 2005). We observed that the CMV
peptide and MOG34–56 share a cross-reactive mimicry epitope
(MOG39–48) (Brok et al., 2007). The cytotoxic T cells that medi-
ate MS-like pathology and disease in the MOG34–56/IFA induced
marmoset EAE model recognize the MOG40–48 epitope (Jages-
sar et al., 2012b). It is therefore tempting to speculate that the
autoreactive CTL that mediate EAE in NHP may be recruited
from the sizeable natural repertoire of effector memory T cells
directed against CMV. Indeed, recent work from Broux and
Hellings shows an important pathogenic role of MOG-specific
CD4+CD28−CX3CR1+ T cells in MS (Broux et al., 2012). These
T cells are thought to sustain chronic inflammatory pathology. As
reviewed elsewhere, CMV may be a main driver of the progres-
sive expansion of the CD28null subset in the aging immune system
(‘T Hart et al., 2013). Interestingly, in an old study the presence of
CMV-reactive T cells within MS brain lesions was already reported
(Scotet et al., 1999). The marmoset model thus supports the pos-
sibility that MS susceptibility may be associated with two herpes
viruses, namely EBV and CMV.
What could be the underlying mechanism? During the co-
evolution with their natural host, CMV and EBV have devel-
oped an elaborate repertoire of strategies to avoid detection by
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the immune system. One of the escape strategies employed by
CMV is minimizing exposure of viral antigens via impairment
of the cell surface expression of peptide-loaded classical MHC
class Ia molecules (HLA-A, -B, -C) with collateral upregulation of
peptide-occupied MHC class Ib (HLA-E/gpUL40) to resist attack
by natural killer cells (Braud et al., 2002). A similar evasion mecha-
nism is employed to avoid immunity at the feto-maternal interface
(Hunt, 2006), toward cancers (Wischhusen et al., 2007) and possi-
bly also within immuno-privileged organs such as the brain (Jiang
and Chess, 2000). It is thus tempting to speculate that mecha-
nisms developed by the immune system to combat immune escape
of CMV may be involved in the induction and/or progression of
autoimmune disease. Is the risk to develop autoimmunity the price
we have to pay for effective protection against the exacerbation of
latent herpesvirus infection?
A T cell subset in the human immune system with a
presumed role in the control of CMV is NK-CTL (Moretta
et al., 2003; Mazzarino et al., 2005). NK-CTL are CD8β+
CTLs that recognize viral peptides presented by the non-
classical MHC-1b molecule HLA-E. The human immune reper-
toire contains a sizeable number of such HLA-E restricted NK-
CTL, which seems to increase with aging (Mazzarino et al.,
2005). It is intriguing that these HLA-E restricted NK-CTL
(CD8β+CD45RA+CD27−CD28−CD56+CCR7−) (Mazzarino
et al., 2005) resemble phenotypically the Caja-E-restricted CTL
(CD4+CD8α+CD45RO−CD27+CD28−CD56+CCR7−) that
mediate EAE in the MOG34–56/IFA induced marmoset EAE model
(Jagessar et al., 2012b). The marmoset cells may also be equivalent
to the already mentioned CD4+CD56+ cytotoxic T cells found
in the MS repertoire, which kill human oligodendrocytes via an
HLA-E restricted mechanism (Zaguia et al., 2013). At this moment
we cannot distinguish between these two options as we could only
use an anti-CD8α mAb for phenotyping of the marmoset cells.
The mAb does not discriminate between CD8αβ heterodimer and
CD8αα homodimer molecules. The latter is transiently expressed
on αβTCR+ T memory effector cells (Madakamutil et al., 2004) as
a ligand of the thymic leukemia antigen TL, a non-classical MHC
molecule that does not bind CD8αβ (Leishman et al., 2001).
Although various APC types are capable of presenting solu-
ble antigens via MHC-I to CD8+ T cells, DC seem to be the
main APC equipped for this task, at least in mice. Also B cells
can cross-present soluble antigen via MHC-I in vitro, albeit only
under particular conditions, including the presence of danger sig-
nals relayed via TLR9 (Jiang et al., 2011), or after infection with
EBV (Jagessar et al., 2013). Important in this context is that latently
EBV-infected B cells escape immunity by down-regulating classi-
cal MHC class Ia (HLA-A, -B, -C) and upregulating MHC class Ib
(HLA-E,-G) molecules (Dutta et al.,2006). It may thus be a reason-
able assumption that latently EBV-infected B cells have the capacity
to present in vivo soluble autoantigen via HLA-E to NK-CTL. This
has actually been shown in marmosets (Jagessar et al., 2013).
Considering the elusive association of EBV with MS the ques-
tion has been raised how the discrepancy between the high preva-
lence of EBV infection (>99%) and the low prevalence of MS
(<1/1000 young adults) in the human population can be explained
(Christensen, 2007). It has been well established that B cells are
particularly effective APC when they can take up soluble anti-
gen via their specific antigen receptor and present it to T cells of
the same specificity (Lanzavecchia and Bove, 1985). As reasoned
above, for acquiring the capacity to present soluble antigen via
MHC class I to CD8+ T cells, the antigen-specific B cell needs
to be infected with EBV. An important variable is thus the chance
that an antigen-specific B cell is infected with EBV. In healthy indi-
viduals the frequency of EBV-infected B cells has been determined
at 1–50 per 106 (Khan et al., 1996). Although the number of B-
cell clones differing in antigen-specificity has been estimated at
around 109, the size of individual clones varies enormously, rang-
ing between 100 cells per clone against new antigens (Quintans
and Lefkovits, 1974) to several thousands for autoantigen-specific
B-cell clones in an autoimmune disease patient (Logtenberg et al.,
1986). Taken together, these findings suggest that the chance that
an autoreactive B-cell clone gets infected with EBV, thereby acquir-
ing the capacity to cross-present soluble antigen to CD8+ T cells,
may be rather low.
In conclusion, we propose that two herpes viruses may be
implicated in the pathogenesis of MS.
CYTOMEGALOVIRUS
HLA-E-restricted NK-CTL play an important role in the lifelong
combat with latent CMV infection. These cells form a broad reser-
voir of highly reactive T cell specificities that progressively expands
with aging (Sylwester et al., 2005). At least one of the specificities
can be stimulated by a cross-reactive peptide (MOG40–48) shared
between a viral antigen (CMV UL86) and an autoantigen unique
to the CNS (MOG).
EPSTEIN BARR VIRUS
We also postulate that this mimicry epitope (MOG40–48) can be
cross-presented by EBV-infected B cells via HLA-E to the HLA-E
restricted NK-CTL. When NK-CTL are activated via this route,
they can find their way into the CNS, where they either directly
or indirectly elicit inflammation and demyelination in white and
gray matter of brain and spinal cord. However, it is unknown
at this stage whether the NK-CTL express the fractalkine recep-
tor CX3CR1, which is prominently expressed on CD4+CD28−
cytotoxic T cells in MS (Broux et al., 2012).
The therapeutic perspective and testable hypothesis follow-
ing from this postulate is that therapeutics specifically targeting
EBV-transformed B cells are a safe and effective treatment for MS.
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